← Back to patent-cliff list
CAS 100-52-7
benzaldehydeBenzaldehydeBitter almond
Codes: RIVA-031, MIRA-012, ENCO-001, (VII)101438-5-a, (II)101438-10-a, (I)101438-13-a, (IX)101438-62-a, (I)101438-70-a, BENV-011, Enalapril-049, Atorvastatin-042, Tamsulosin Hydrochloride-020 +11 more
Application context (from source-drug indications)
Pulmonary embolismRivaroxabanStrokeRivaroxabanCongenital heart defectRivaroxabanThrombosisRivaroxabanVenous thromboembolismRivaroxabanCoronary artery diseaseRivaroxabanNeurogenic bladder dysfunctionMirabegronOveractive bladderMirabegronNon-small cell lung cancerEncorafenibColorectal cancerEncorafenibThyroid cancerEncorafenibMelanomaEncorafenibBreast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylatePlaque psoriasisBenvitimodAtopic dermatitisBenvitimodPsoriasisBenvitimodCutaneous T-cell lymphomaBenvitimodMycosis fungoidesBenvitimodMeleda diseaseBenvitimodCardiac and vascular disordersAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilHypertensionAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilHyperlipidaemiaAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilHeart diseaseAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilErectile dysfunctionTadalafil/TamsulosinBenign prostatic hyperplasiaTadalafil/TamsulosinBladder cancerDocetaxel polymeric micelle (Samyang Biopharmaceuticals)Head and neck cancerDocetaxel polymeric micelle (Samyang Biopharmaceuticals)Head and neck squamous cell carcinomaDocetaxel polymeric micelle (Samyang Biopharmaceuticals)Solid tumourDocetaxel polymeric micelle (Samyang Biopharmaceuticals)HypotensionEphedrine SulfateLower urinary tract symptomsSolifenacin Succinate/Tamsulosin HydrochlorideBenign prostatic hyperplasiaSolifenacin Succinate/Tamsulosin HydrochlorideOveractive bladderSolifenacin Succinate/Tamsulosin HydrochlorideDrug-related adverse effects and reactionsSolifenacin Succinate/Tamsulosin HydrochlorideBladder neck obstructionSolifenacin Succinate/Tamsulosin HydrochlorideOsteoporosisIbandronate Sodium Hydrate/ColecalciferolBenign prostatic hyperplasiaDutasteride/Tamsulosin HydrochlorideEssential hypertensionEnalapril Maleate/Folic AcidHyperlipidaemiaAtorvastatin strontiumSubarachnoid haemorrhageAtorvastatin strontiumHypertensionAtorvastatin strontiumBenign prostatic hyperplasiaTamsulosin HydrochlorideUrinary tract infectionTamsulosin HydrochlorideUrinary retentionTamsulosin HydrochlorideInguinal herniaTamsulosin HydrochlorideVoiding dysfunctionTamsulosin HydrochlorideLower urinary tract symptomsTamsulosin HydrochlorideHeart failureEnalapril MaleateHypertensionEnalapril MaleateMyocardial infarctionEnalapril MaleateAngina pectorisEnalapril MaleateLeft ventricular dysfunctionEnalapril MaleateSolid tumourEnalapril MaleatePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxelOsteoporosisIbandronate Sodium HydratePostmenopausal osteoporosisIbandronate Sodium HydrateHypercalcaemiaIbandronate Sodium HydrateBone injuryIbandronate Sodium HydrateBreast cancerIbandronate Sodium HydrateMetastatic cancerIbandronate Sodium HydrateNon-small cell lung cancerDocetaxel （Beihai）Prostate cancerDocetaxel （Beihai）Castration-resistant prostate cancerDocetaxel （Beihai）Breast cancerDocetaxel （Beihai）Head and neck cancerDocetaxel （Beihai）Head and neck squamous cell carcinomaDocetaxel （Beihai）Type 2 diabetesMitiglinideDiabetesMitiglinide分离性焦虑S-fluoxetineAnxietyS-fluoxetineAnxiety disorderS-fluoxetine分离性焦虑R-fluoxetineAnxietyR-fluoxetineAnxiety disorderR-fluoxetinePulmonary arterial hypertensionZamicastatLung diseaseZamicastatHeart failureZamicastatNon-small cell lung cancerPlinabulinNeutropeniaPlinabulinMultiple myelomaPlinabulinLung cancerPlinabulinSmall cell lung cancerPlinabulinMerkel细胞癌Plinabulin
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Rivaroxaban | Tier A — Act now | 2026 |
| Mirabegron | Tier B — Position early | 2029 |
| Encorafenib | Tier C — Watch / trade | 2030 |
| Paclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
| Benvitimod | Tier C — Watch / trade | - |
| Atorvastatin/Hydrochlorothiazide/Aspirin/Enalapril | Tier C — Watch / trade | - |
| Tadalafil/Tamsulosin | Tier C — Watch / trade | - |
| Docetaxel polymeric micelle (Samyang Biopharmaceuticals) | Tier C — Watch / trade | - |
| Ephedrine Sulfate | Tier C — Watch / trade | - |
| Solifenacin Succinate/Tamsulosin Hydrochloride | Tier C — Watch / trade | - |
| Ibandronate Sodium Hydrate/Colecalciferol | Tier C — Watch / trade | - |
| Dutasteride/Tamsulosin Hydrochloride | Tier C — Watch / trade | - |
| Enalapril Maleate/Folic Acid | Tier C — Watch / trade | - |
| Atorvastatin strontium | Tier C — Watch / trade | - |
| Tamsulosin Hydrochloride | Tier C — Watch / trade | - |
| Enalapril Maleate | Tier C — Watch / trade | - |
| Paclitaxel | Tier B — Position early | - |
| Ibandronate Sodium Hydrate | Tier C — Watch / trade | - |
| Docetaxel （Beihai） | Tier C — Watch / trade | - |
| Mitiglinide | Tier C — Watch / trade | - |
| S-fluoxetine | Tier C — Watch / trade | - |
| R-fluoxetine | Tier C — Watch / trade | - |
| Zamicastat | Tier C — Watch / trade | - |
| Plinabulin | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
5-chlorothiophene-2-carbonyl chloride→benzyl (4-(3-oxomorpholino)phenyl)carbamate→(S)-2-(chloromethyl)oxirane→benzaldehyde→(S,E)-1-(benzylideneamino)-3-chloropropan-2-ol→(S)-1-amino-3-chloropropan-2-ol hydrochloride→(S)-5-chloro-N-(3-chloro-2-hydroxypropyl)thiophene-2-carboxamide→(S)-1-chloro-3-(5-chlorothiophene-2-carboxamido)propan-2-yl acetate
benzaldehyde→isopropylhydrazine hydrochloride→(E)-1-benzylidene-2-isopropylhydrazine→2-(ethoxymethylene)malononitrile→(E)-2-((2-benzylidene-1-isopropylhydrazinyl)methylene)malononitrile→3-amino-1-isopropyl-1H-pyrazole-4-carbonitrile→1-(3-amino-1-isopropyl-1H-pyrazol-4-yl)ethan-1-one→1-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)ethan-1-one→(Z)-3-(dimethylamino)-1-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)prop-2-en-1-one→guanidine hydrochloride→4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-amine→4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-ol→2-chloro-4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidine→methyl (S)-(1-aminopropan-2-yl)carbamate hydrochloride→methyl (S)-(1-((4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate→tert-butyl (5-chloro-2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate→methyl (S)-(1-((4-(3-(3-((tert-butoxycarbonyl)amino)-5-chloro-2-fluorophenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate→methyl (S)-(1-((4-(3-(3-amino-5-chloro-2-fluorophenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate→methyl (S)-(1-((4-(3-(5-chloro-2-fluoro-3-(N-(methylsulfonyl)methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate→2-bromo-4-chloro-1-fluorobenzene→3-bromo-5-chloro-2-fluorobenzoic acid→tert-butyl (3-bromo-5-chloro-2-fluorophenyl)carbamate→4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)
(1S,2R)-2-phenylcyclohexan-1-ol→2-(Benzyloxy)acetyl chloride→(1S,2R)-2-phenylcyclohexyl 2-(benzyloxy)acetate→(1S,2R)-2-phenylcyclohexyl 2-hydroxyacetate→(3R,4S)-3-hydroxy-4-phenylazetidin-2-one→(1S,2R)-2-phenylcyclohexyl 2-[(triisopropylsilyl)oxy]acetate→1,1,1-Trimethyl-N-[(E)-phenylmethylidene]silanamine→Benzaldehyde→(3R,4S)-4-Phenyl-3-{[tris(propan-2-yl)silyl]oxy}azetidin-2-one→(3R,4S)-3-(1-Ethoxyethoxy)-4-phenylazetidin-2-one→alpha-Chlorobenzaldehyde→1-Benzoyl-3(R)-(1-ethoxyethoxy)-4(S)-phenylazetidin-2-one→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-Bis(acetyloxy)-1,15-dihydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(2alpha,5beta,7beta,10beta,13alpha)-4,10-Diacetoxy-13-[[(2R,3S)-3-(benzoylamino)-2-(1-ethoxyethoxy)-3-phenylpropanoyl]oxy]-1-hydroxy-9-oxo-7-[(triethylsilyl)oxy]-5,20-epoxytax-11-en-2-yl benzoate
(4S,5R)-3-(2-bromoacetyl)-4-methyl-5-phenyl-1,3-oxazolidin-2-one→Benzaldehyde→(4S,5R)-3-[(2S,3R)-2-bromo-3-hydroxy-3-phenylpropanoyl]-4-methyl-5-phenyl-1,3-oxazolidin-2-one→Ethyl (2R,3R)-3-phenyloxirane-2-carboxylate→(4S,5R)-3-(tert-Butoxycarbonyl)-2,2-dimethyl-4-phenyl-1,3-oxazolidine-5-carboxylic acid→Ethyl (2R,3S)-3-azido-2-hydroxy-3-phenylpropanoate→Ethyl (2R,3S)-3-amino-2-hydroxy-3-phenylpropanoate→Ethyl (2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate→3-tert-butyl 5-ethyl (4S,5R)-2,2-dimethyl-4-phenyl-1,3-oxazolidine-3,5-dicarboxylate→(2alpha,5beta,7beta,10beta,13alpha)-4,10-Bis(acetyloxy)-1,13-dihydroxy-9-oxo-7-[[(2,2,2-trichloroethoxy)carbonyl]oxy]-5,20-epoxytax-11-en-2-yl benzoate→5-(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-2-(benzoyloxy)-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-9-{[(2,2,2-trichloroethoxy)carbonyl]oxy}-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-15-yl 3-tert-butyl (4S,5R)-2,2-dimethyl-4-phenyl-1,3-oxazolidine-3,5-dicarboxylate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-15-{[(2R,3S)-3-amino-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-9-{[(2,2,2-trichloroethoxy)carbonyl]oxy}-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1-hydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-9-{[(2,2,2-trichloroethoxy)carbonyl]oxy}-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Qualified Partner — East China API Works | 4-(4-Aminophenyl)morpholin -3-one Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | (S)-(+)-N-(2,3-Epoxypropyl)phthalimide Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 5-Chlorothiophene-2-carboxylic acid Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 5-Chlorothiophene-2-carbonyl chloride Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 2-[[(5S)-2-0x0-3-[4-(3-0xo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-1H-isoindole-1,3(2H)-dione Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 4-[4-[(5S)-5-(Aminomethyl)-2-0xo-3-oxazolidinyl]phenyl] -3-morpholinone hydrochloride Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 2-[(2R)-2-Hydroxy-3-[[4-(3-oxo-4-Morpho linyl)phenyl]aMino]propyl]-1H-isoindole-1 ,3(2H)-dione Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.